SOURCE: Pulse Beverage Corporation

Pulse Beverage Corporation

February 29, 2012 09:00 ET

Pulse Secures Distribution in Minnesota Through Norri Distributing

DENVER, CO--(Marketwire - Feb 29, 2012) - The Pulse Beverage Corporation (OTCBB: PLSB) ("Pulse"), makers of Cabana™ 100% Natural Lemonade and Pulse® NutriPurpose™ brand beverages, today announced that it has secured distribution in Minnesota, through Norri Distributing based in northern Minnesota and established in 1951. Norri distributes a few major brands of beer including Miller and non-alcoholic beverages to the northern region of Minnesota. This agreement fills in a missing area in Minnesota that Bernicks Distributing does not reach. Norri recently bought out a local competitor who has increased Norri's breadth of brands and reach and they are committed to aggressively grow both the beer and non-alcoholic ends of their business. Bob Norri, CEO of Norri Distributing, said, "We look forward to selling and growing Cabana with its eye catching packaging and awesome taste."

Bob Yates, CEO of Pulse, said, "We are looking forward to working with Norri Distributing. They are a high quality distributor with a great reputation and have an aggressive approach to the market which will yield our partnership great rewards."

Details of the Company's business and agreements can be found as part of the Company's continuous public disclosure as a reporting issuer under the Securities Exchange Act of 1934 filed with the Securities and Exchange Commission's ("SEC") EDGAR database. For more information, please visit: www.pulsebeverage.com.

About The Pulse Beverage Corporation (OTCBB: PLSB)
The Pulse Beverage Corporation is an emerging growth beverage company that manufactures, distributes and markets Cabana™ 100% Natural Lemonade and is preparing to "red carpet" distribute its flagship beverage product PULSE® NutriPurpose™ brand originally developed by a major healthcare company. For more information: www.pulsebeverage.com or email info@pulsebeverage.com.

The above statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Forward-Looking Statements
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, regulatory incentives, the development of new business opportunities, and projected costs, revenue, profits and results operations. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects and development stage companies. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

ON BEHALF OF THE BOARD

Robert E. Yates, Chief Executive Officer

Contact Information